Matches in SemOpenAlex for { <https://semopenalex.org/work/W2400808625> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2400808625 endingPage "800" @default.
- W2400808625 startingPage "795" @default.
- W2400808625 abstract "Myeloablation and immunosuppression were considered to be the two major roles of the conditioning regimens for allogeneic stem cell transplantation to facilitate engraftment. It has turned out, however, that immunosuppression is more important and myeloablation is not necessary for engraftment. At the same time, it is considered that the major anti-tumor effect of allogeneic stem cell transplantation depends on the graft-versus-leukemia effect, not on the conditioning regimen itself. In patients with CML who relapsed after allogeneic transplantation, for example, infusion of donor lymphocytes can induce a second complete remission. Non-myeloablative stem cell transplantation (NST) was developed in the late 90s based on these theories. Low-dose, less toxic, so-called non-myeloablative preparative regimens have been designed not to eradicate the malignancies, but to provide sufficient immunosuppression to allow donor cells to engraft, while the graft-versus-malignancy effects eradicate the tumor. This strategy permits allogeneic transplantation to be used in patients who are not eligible for conventional, often myeloablative, transplantation because of advanced age or organ dysfunction. Non-myeloablative preparative regimens contain purine analogs, such as fludarabine or cladribine. The NST regimen being used at the National Cancer Center Hospital, Tokyo, Japan, consists of cladribine (0.11 mg/kg x 6 days), busulfan (4 mg/kg x 2 days) and rabbit anti-thymocyte globulin (2.5 mg/kg x 4 days). We enrolled 6 patients in this NST protocol so far: 1 with severe aplastic anemia (sibling-PBSCT), 2 with MDS-RA (1 for sibling-PBSCT and 1 for matched uBMT), 1 with AML-CR2 (matched uBMT), 1 with AML-CR3 (sibling-PBSCT), and 1 with relapsed AML (mismatched related PBSCT). All patients achieved engraftment within 14 days with complete donor chimerism. In addition to leukemias, a graft-versus-malignancy effect was also reported in allogeneic NST of solid tumors, such as renal cell carcinoma and malignant melanoma. The long-term efficacy of NST remains to be determined, and further clinical trials are warranted." @default.
- W2400808625 created "2016-06-24" @default.
- W2400808625 creator A5065589058 @default.
- W2400808625 creator A5075198979 @default.
- W2400808625 date "2000-06-01" @default.
- W2400808625 modified "2023-09-23" @default.
- W2400808625 title "[Non-myeloablative stem cell transplant]." @default.
- W2400808625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10897204" @default.
- W2400808625 hasPublicationYear "2000" @default.
- W2400808625 type Work @default.
- W2400808625 sameAs 2400808625 @default.
- W2400808625 citedByCount "0" @default.
- W2400808625 crossrefType "journal-article" @default.
- W2400808625 hasAuthorship W2400808625A5065589058 @default.
- W2400808625 hasAuthorship W2400808625A5075198979 @default.
- W2400808625 hasConcept C126322002 @default.
- W2400808625 hasConcept C141071460 @default.
- W2400808625 hasConcept C143998085 @default.
- W2400808625 hasConcept C2776694085 @default.
- W2400808625 hasConcept C2776755627 @default.
- W2400808625 hasConcept C2777408962 @default.
- W2400808625 hasConcept C2779200787 @default.
- W2400808625 hasConcept C2779263901 @default.
- W2400808625 hasConcept C2780252810 @default.
- W2400808625 hasConcept C2780611847 @default.
- W2400808625 hasConcept C28328180 @default.
- W2400808625 hasConcept C2911091166 @default.
- W2400808625 hasConcept C54355233 @default.
- W2400808625 hasConcept C71924100 @default.
- W2400808625 hasConcept C86803240 @default.
- W2400808625 hasConceptScore W2400808625C126322002 @default.
- W2400808625 hasConceptScore W2400808625C141071460 @default.
- W2400808625 hasConceptScore W2400808625C143998085 @default.
- W2400808625 hasConceptScore W2400808625C2776694085 @default.
- W2400808625 hasConceptScore W2400808625C2776755627 @default.
- W2400808625 hasConceptScore W2400808625C2777408962 @default.
- W2400808625 hasConceptScore W2400808625C2779200787 @default.
- W2400808625 hasConceptScore W2400808625C2779263901 @default.
- W2400808625 hasConceptScore W2400808625C2780252810 @default.
- W2400808625 hasConceptScore W2400808625C2780611847 @default.
- W2400808625 hasConceptScore W2400808625C28328180 @default.
- W2400808625 hasConceptScore W2400808625C2911091166 @default.
- W2400808625 hasConceptScore W2400808625C54355233 @default.
- W2400808625 hasConceptScore W2400808625C71924100 @default.
- W2400808625 hasConceptScore W2400808625C86803240 @default.
- W2400808625 hasIssue "6" @default.
- W2400808625 hasLocation W24008086251 @default.
- W2400808625 hasOpenAccess W2400808625 @default.
- W2400808625 hasPrimaryLocation W24008086251 @default.
- W2400808625 hasRelatedWork W1995219753 @default.
- W2400808625 hasRelatedWork W2026006754 @default.
- W2400808625 hasRelatedWork W2092132051 @default.
- W2400808625 hasRelatedWork W2118322536 @default.
- W2400808625 hasRelatedWork W214818693 @default.
- W2400808625 hasRelatedWork W2360634842 @default.
- W2400808625 hasRelatedWork W2400808625 @default.
- W2400808625 hasRelatedWork W2413424438 @default.
- W2400808625 hasRelatedWork W2414700771 @default.
- W2400808625 hasRelatedWork W3180209262 @default.
- W2400808625 hasVolume "27" @default.
- W2400808625 isParatext "false" @default.
- W2400808625 isRetracted "false" @default.
- W2400808625 magId "2400808625" @default.
- W2400808625 workType "article" @default.